Skip to content
HowShorted

Avidity Biosciences, Inc. short interest in 2022

In 2022, Avidity Biosciences, Inc.'s disclosed short interest ran from 8.04% of shares outstanding on 14 Jan 2022 to 15.20% on 30 Dec 2022, a change of +7.16 percentage points. The year's high was 15.20% on 30 Dec 2022 and its low 7.72% on 31 Jan 2022, averaging 9.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.17 days on 29 Jul 2022. Full history: Avidity Biosciences, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Avidity Biosciences, Inc. in 2022

2022 in figures

Start of year
8.04% (14 Jan 2022)
End of year
15.20% (30 Dec 2022)
Change
+7.16 pp
High
15.20% (30 Dec 2022)
Low
7.72% (31 Jan 2022)
Average
9.99%
Highest days to cover
25.17 (29 Jul 2022)
SEC filings marked
8

Every report in 2022

Avidity Biosciences, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.04%16.69
31 Jan 20227.72%12.07
15 Feb 20227.96%15.95
28 Feb 20228.11%8.14
15 Mar 20228.28%19.4110-K filed, results (8-K)
31 Mar 20228.39%19.10
14 Apr 20228.37%19.04
29 Apr 20228.25%21.48
13 May 20228.63%15.2110-Q filed, results (8-K)
31 May 20229.45%13.40
15 Jun 20229.90%18.81
30 Jun 202211.40%7.23
15 Jul 202211.85%24.39
29 Jul 202211.18%25.17
15 Aug 202210.68%16.5210-Q filed, results (8-K)
31 Aug 202210.10%20.73
15 Sep 202210.16%15.71
30 Sep 20228.80%5.76
14 Oct 20229.45%13.31
31 Oct 202210.20%8.16
15 Nov 202212.91%16.1410-Q filed, results (8-K)
30 Nov 202212.88%10.52
15 Dec 202211.95%1.10
30 Dec 202215.20%2.93

See also: Avidity Biosciences, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.